8/31/2010

Roche Holding's breast cancer drug Herceptin and Sanofi-Aventis' heart drug Multaq are on the FDA's quarterly list of treatments being investigated for possible safety risks. The list also includes Pfizer's antibiotic Cleocin, Merck & Co.'s contraceptive Implanon and Novartis' cancer treatment Afinitor.

Full Story:
Reuters

Related Summaries